Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES WESLEY SUBLETT

Allopathic & Osteopathic Physicians Allergy & Immunology

NPI
1255474136
CMS profile
102116
Location
LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2022 · Entire year

$63,668.84

109 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2022 · entire year · sorted by reported total

By paying entity

PY2022 · entire year · sorted by reported total

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES WESLEY SUBLETT

NPI 1255474136 · CMS profile ID 102116

Allopathic & Osteopathic Physicians / Allergy & Immunology

LOUISVILLE, KY

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1255474136?year=2022&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES WESLEY SUBLETT, NPI 1255474136, CMS profile ID 102116. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1255474136?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
APA 7
IndustryPayments. (2026). JAMES WESLEY SUBLETT, NPI 1255474136, CMS profile ID 102116. General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1255474136?year=2022&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c.
Bluebook
JAMES WESLEY SUBLETT, NPI 1255474136, CMS profile ID 102116, IndustryPayments, General Payments, PY2022; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 3; records 51–100 of 109 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/df01c2f8-dc1f-4e79-96cb-8208beaf143c. https://industrypayments.org/provider/npi-1255474136?year=2022&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2022

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2022 · Physicians and non-physician practitioners · CMS publication 2026-06-30

109 matching records · $63,668.84 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 109 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 109.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amgen Inc. $2,150.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351871 CMS
AstraZeneca Pharmaceuticals LP $2,150.0006/30/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914738765 CMS
OptiNose US, Inc. $19.7606/28/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928095355 CMS
Regeneron Healthcare Solutions, Inc. $15.3506/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433641 CMS
Amgen Inc. $121.8606/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351873 CMS
AstraZeneca Pharmaceuticals LP $121.8606/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915837235 CMS
GENZYME CORPORATION $5,181.0006/17/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024897 CMS
GENZYME CORPORATION $955.9906/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024899 CMS
GENZYME CORPORATION $346.7006/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024901 CMS
GENZYME CORPORATION $446.6906/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024903 CMS
GENZYME CORPORATION $137.1906/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024905 CMS
GENZYME CORPORATION $49.1006/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024907 CMS
GENZYME CORPORATION $60.3806/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024909 CMS
GENZYME CORPORATION $69.0006/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024911 CMS
GENZYME CORPORATION $39.1506/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024913 CMS
GENZYME CORPORATION $1,635.0006/15/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024859 CMS
ALK-Abello, Inc $21.0106/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 905016755 CMS
GENZYME CORPORATION $1,635.0006/07/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024857 CMS
GlaxoSmithKline, LLC. $11.8905/31/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 944752875 CMS
Regeneron Healthcare Solutions, Inc. $21.4605/27/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433632 CMS
Teva Pharmaceuticals USA, Inc. $20.6105/26/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954410189 CMS
PFIZER INC. $15.4305/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949615439 CMS
AstraZeneca Pharmaceuticals LP $1,050.0005/23/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915012507 CMS
AstraZeneca Pharmaceuticals LP $1,600.0005/22/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915362671 CMS
Pharming Healthcare, Inc. $19.4905/19/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 907881231 CMS
AstraZeneca Pharmaceuticals LP $12.7505/17/2022 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914674329 CMS
GENZYME CORPORATION $112.1405/17/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024849 CMS
GENZYME CORPORATION $2,452.0005/17/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939024851 CMS
Regeneron Healthcare Solutions, Inc. $11.0205/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433623 CMS
OptiNose US, Inc. $20.9505/12/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928095311 CMS
OptiNose US, Inc. $1,840.0005/06/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928095447 CMS
OptiNose US, Inc. $1,840.0005/05/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928095441 CMS
Teva Pharmaceuticals USA, Inc. $13.4105/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954410213 CMS
AstraZeneca Pharmaceuticals LP $12.3104/29/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915013457 CMS
Regeneron Healthcare Solutions, Inc. $14.8504/21/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433615 CMS
AstraZeneca Pharmaceuticals LP $30.7504/18/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 914814497 CMS
AstraZeneca Pharmaceuticals LP $124.9904/14/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915487079 CMS
Amgen Inc. $13.4404/13/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351867 CMS
Teva Pharmaceuticals USA, Inc. $12.6104/05/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954410307 CMS
Regeneron Healthcare Solutions, Inc. $14.1503/25/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433607 CMS
OptiNose US, Inc. $19.9403/22/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 928095291 CMS
PFIZER INC. $2,775.0003/11/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 949630349 CMS
Incyte Corporation $1,900.0003/08/2022 Consulting Fee No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 942882813 CMS
Teva Pharmaceuticals USA, Inc. $11.1603/08/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 954410187 CMS
Amgen Inc. $15.3203/03/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351869 CMS
CSL Behring $25.5203/02/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 940918897 CMS
LEO Pharma Inc. $25.6902/24/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 936293119 CMS
AstraZeneca Pharmaceuticals LP $2,150.0002/16/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 915453685 CMS
Regeneron Healthcare Solutions, Inc. $15.2902/11/2022 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 927433599 CMS
Amgen Inc. $2,150.0002/10/2022 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 939351863 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $71,012.73 116
PY2020 $32,854.99 35
PY2021 $24,523.82 70
PY2022 $63,668.84 109
PY2023 $83,312.80 113
PY2024 $174,178.02 180
PY2025 $138,465.34 160

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $197,607.96 19
PY2024 Principal investigator $39,838.10 12
PY2023 Principal investigator $106,018.59 15
PY2022 Principal investigator $114,636.76 12
PY2021 Principal investigator $195,433.27 40
PY2020 Principal investigator $259,596.60 34
PY2019 Principal investigator $236,440.68 22

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

19 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 GENZYME CORPORATION $13,859.00 11/17/2025 Non-covered Recipient Entity
Family Allergy And Asthma
A Randomized, Double-Blind, Placebo Controlled Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Patients With Uncontrolled Moderate to Severe Asthma No dispute reported 06/30/2026 1226137894
Principal investigator 1 AstraZeneca UK Limited $19,356.00 09/26/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
a phase two a,randomized,double blind,placebo controlled study to assess efficacy and safety of atuliflapon given orally once daily for twelve weeks in adults with moderate to severe uncontrolled asthma No dispute reported 06/30/2026 1185550087
Principal investigator 1 GlaxoSmithKline, LLC. $8,500.00 08/27/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192174654
Principal investigator 1 GlaxoSmithKline, LLC. $3,300.00 08/27/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
A PROSPECTIVE, REAL-WORLD, INTERVENTIONAL STUDY TO EVALUATE THE EFFECT No dispute reported 06/30/2026 1192174658
Principal investigator 1 Novartis Pharmaceuticals Corporation $274.21 08/15/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
A Three-year, Multi-center, Double-blind, Extension Study to Evaluate the Long-term Safety and Efficacy of Ligelizumab in Patients Who Completed Ligelizumab's Phase III Studies in Food Allergy No dispute reported 06/30/2026 1190301761
Principal investigator 1 Novartis Pharmaceuticals Corporation $28,617.48 08/01/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
A US Phase 3b, Multi-center, Randomized, Double-blind, Double-Dummy Study to Evaluate Efficacy of Remibrutinib Compared to Dupilumab at Early Timepoints in Adults With Chronic Spontaneous Urticaria Inadequately Controlled by Second Generation H1-Antihista No dispute reported 06/30/2026 1190301759
Principal investigator 1 GlaxoSmithKline, LLC. $2,082.94 07/16/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174646
Principal investigator 1 AstraZeneca Pharmaceuticals LP $13,602.57 05/09/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
A Randomized Double Blind Double Dummy Parallel Group Multicenter 24 to 52 Week Variable Length Study to Assess the Efficacy and Safety of Budesonide Glycopyrronium and Formoterol Fumarate Metered Dose Inhaler No dispute reported 06/30/2026 1185550083
Principal investigator 1 AstraZeneca Pharmaceuticals LP $6,499.88 05/02/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A Randomized, Placebo-controlled, Double-blind, Multicenter, 12 Week, 3-Way, Partial-replicate Crossover Pharmacodynamic Study to Assess the Equivalence of Budesonide and Albuterol (BDA) Delivered by MDI HFO Compared with BDA Delivered by MDI HFA in Participants with Asthma No dispute reported 06/30/2026 1185550089
Principal investigator 1 AstraZeneca Pharmaceuticals LP $35,036.26 04/28/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA
The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic corticosteroid or monoclonal antibod No dispute reported 06/30/2026 1185550085
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $9,500.00 04/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184181688
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $974.00 04/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184181690
Principal investigator 1 Regeneron Pharmaceuticals, Inc. $2,535.00 04/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK LLC
AIM4: NEXT STEP - ASTHMA UNCONTROLLED WITH ICS IN MEDIUM DOSE (GINA 4): NEXT STEP; EFFICACY OF DUPILUMAB ADDED TO MEDIUM DOSE ICS/LABA IN COMPARISON TO ICS DOSE ESCALATION TO HIGH DOSE ICS/LABA IN PATIENTS WITH UNCONTROLLED ASTHMA No dispute reported 06/30/2026 1184181692
Principal investigator 1 GlaxoSmithKline, LLC. $156.60 03/27/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174452
Principal investigator 1 GlaxoSmithKline, LLC. $78.30 03/27/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174639
Principal investigator 1 GlaxoSmithKline, LLC. $156.60 03/27/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174642
Principal investigator 1 GlaxoSmithKline, LLC. $175.50 02/04/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174634
Principal investigator 1 Amgen Inc. $45,610.99 01/27/2025 Non-covered Recipient Entity
FAMILY ALLERGY AND ASTHMA RESEARCH INSTITUTE
A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma No dispute reported 06/30/2026 1246641349
Principal investigator 1 GlaxoSmithKline, LLC. $7,292.63 01/09/2025 Non-covered Recipient Entity
CRN CLINICAL RESEARCH NETWORK
A RANDOMIZED, DOUBLE-BLIND, PARALLEL GROUP, MULTI-CENTER STUDY TO EVAL No dispute reported 06/30/2026 1192174649